These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37302771)

  • 1. Pharmacokinetic interaction between rifampicin and clindamycin in staphylococcal osteoarticular infections.
    Goulenok T; Seurat J; Selle A; Jullien V; Leflon-Guibout V; Grall N; Lescure FX; Lepeule R; Bertrand J; Fantin B; Burdet C; Lefort A
    Int J Antimicrob Agents; 2023 Aug; 62(2):106885. PubMed ID: 37302771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic variability of clindamycin and influence of rifampicin on clindamycin concentration in patients with bone and joint infections.
    Curis E; Pestre V; Jullien V; Eyrolle L; Archambeau D; Morand P; Gatin L; Karoubi M; Pinar N; Dumaine V; Nguyen Van JC; Babinet A; Anract P; Salmon D
    Infection; 2015 Aug; 43(4):473-81. PubMed ID: 25837442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dramatic reduction of clindamycin serum concentration in staphylococcal osteoarticular infection patients treated with the oral clindamycin-rifampicin combination.
    Bernard A; Kermarrec G; Parize P; Caruba T; Bouvet A; Mainardi JL; Sabatier B; Nich C
    J Infect; 2015 Aug; 71(2):200-6. PubMed ID: 25936632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of the clindamycin administration route on the magnitude of clindamycin-rifampicin interaction: a prospective pharmacokinetic study.
    Zeller V; Magreault S; Heym B; Salmon D; Kitzis MD; Billaud E; Marmor S; Jannot AS; Salomon L; Jullien V
    Clin Microbiol Infect; 2021 Dec; 27(12):1857.e1-1857.e7. PubMed ID: 33915288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of current dosing guidance for oral rifampicin treatment in adult patients with osteoarticular infections.
    Marsot A; Ménard A; Dupouey J; Allanioux L; Blin O; Guilhaumou R
    Br J Clin Pharmacol; 2020 Nov; 86(11):2319-2324. PubMed ID: 32330996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro pharmacokinetic/pharmacodynamic activity of NXL103 versus clindamycin and linezolid against clinical Staphylococcus aureus and Streptococcus pyogenes isolates.
    Vidaillac C; Parra-Ruiz J; Winterfield P; Rybak MJ
    Int J Antimicrob Agents; 2011 Oct; 38(4):301-6. PubMed ID: 21764263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clindamycin combination treatment for the treatment of bone and joint infections caused by clindamycin-susceptible, erythromycin-resistant Staphylococcus spp.
    Bonnaire A; Vernet-Garnier V; Lebrun D; Bajolet O; Bonnet M; Hentzien M; Ohl X; Diallo S; Bani-Sadr F
    Diagn Microbiol Infect Dis; 2021 Jan; 99(1):115225. PubMed ID: 33099073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic/Pharmacodynamic Target Attainment of Vancomycin, at Three Reported Infusion Modes, for Methicillin-Resistant
    Song X; Han M
    Front Cell Infect Microbiol; 2022; 12():874401. PubMed ID: 35873144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological indices and pulmonary distribution of rifampicin after repeated oral administration in healthy foals.
    Berlin S; Kirschbaum A; Spieckermann L; Oswald S; Keiser M; Grube M; Venner M; Siegmund W
    Equine Vet J; 2017 Sep; 49(5):618-623. PubMed ID: 28063154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacodynamics of minocycline alone and in combination with rifampicin against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection.
    Noel AR; Attwood M; Bowker KE; MacGowan AP
    J Antimicrob Chemother; 2021 Jun; 76(7):1840-1844. PubMed ID: 33975336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacokinetics and pharmacodynamics of antimicrobial therapy used in child osteoarticular infections].
    Cohen R; Grimprel E
    Arch Pediatr; 2007 Oct; 14 Suppl 2():S122-7. PubMed ID: 17956820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clindamycin-rifampin combination therapy for staphylococcal periprosthetic joint infections: a retrospective observational study.
    Leijtens B; Elbers JBW; Sturm PD; Kullberg BJ; Schreurs BW
    BMC Infect Dis; 2017 May; 17(1):321. PubMed ID: 28464821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibiotic susceptibility among Staphylococcus epidermidis isolated from prosthetic joint infections, with focus on doxycycline.
    Hamad T; Hellmark B; Nilsdotter-Augustinsson Å; Söderquist B
    APMIS; 2015 Dec; 123(12):1055-60. PubMed ID: 26547372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergy between gemifloxacin and trimethoprim/sulfamethoxazole against community-associated methicillin-resistant Staphylococcus aureus.
    Leonard SN; Kaatz GW; Rucker LR; Rybak MJ
    J Antimicrob Chemother; 2008 Dec; 62(6):1305-10. PubMed ID: 18801920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics and pharmacokinetic/pharmacodynamic evaluation of marbofloxacin against Coagulase-negative staphylococci, Staphylococcus aureus and Mycoplasma agalactiae pathogens in goats.
    Serrano-Rodríguez JM; Fernández-Varón E; Rodríguez CMC; Andrés-Larrea MIS; Rubio-Langre S; de la Fe C; Dova SW; Bhardwaj P; Sidhu PK; Litterio NJ; Lorenzutti AM
    Res Vet Sci; 2023 Jun; 159():1-10. PubMed ID: 37060837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Community-acquired methicillin-resistant Staphylococcus aureus in bone and joint infections: development of rifampicin resistance.
    Donaldson AD; Chan RC; Gosbell IB
    Med J Aust; 2006 Feb; 184(4):196. PubMed ID: 16489910
    [No Abstract]   [Full Text] [Related]  

  • 17. Investigation on rifampicin administration from the standpoint of pharmacokinetics/pharmacodynamics in a neutropenic murine thigh infection model.
    Hirai J; Hagihara M; Kato H; Sakanashi D; Nishiyama N; Koizumi Y; Yamagishi Y; Suematsu H; Hanaki H; Mikamo H
    J Infect Chemother; 2016 Jun; 22(6):387-94. PubMed ID: 27029221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates.
    Sambatakou H; Giamarellos-Bourboulis EJ; Grecka P; Chryssouli Z; Giamarellou H
    J Antimicrob Chemother; 1998 Mar; 41(3):349-55. PubMed ID: 9578161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rifabutin versus rifampicin bactericidal and antibiofilm activities against clinical strains of Staphylococcus spp. isolated from bone and joint infections.
    Thill P; Robineau O; Roosen G; Patoz P; Gachet B; Lafon-Desmurs B; Tetart M; Nadji S; Senneville E; Blondiaux N
    J Antimicrob Chemother; 2022 Mar; 77(4):1036-1040. PubMed ID: 35028671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model.
    Baldoni D; Furustrand Tafin U; Aeppli S; Angevaare E; Oliva A; Haschke M; Zimmerli W; Trampuz A
    Int J Antimicrob Agents; 2013 Sep; 42(3):220-5. PubMed ID: 23880168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.